Myelodysplastic Syndrome Clinical Trial
JSP191 (Briquilimab) in Subjects With LR-MDS
Summary
A Phase 1 study in subjects with LR-MDS to assess the safety and tolerability of JSP191 as a second-line therapy.
Full Description
An open-label, single-arm, dose-escalation study designed to determine the potential safety, efficacy, maximum tolerated dose (MTD) or optimal biologic dose (OBD), and recommended phase 2 dose (RP2D) of JSP191 (briquilimab) monotherapy for LR-MDS subjects with documented cytopenia (red blood cell-transfusion dependent, thrombocytopenia, and/or neutropenia).
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years
MDS with IPSS-R very low, low, or intermediate risk features
Symptomatic cytopenias
Women of childbearing potential (WOCBP) must agree to use an oral or implanted contraceptive, a double-barrier method of birth control, or an intrauterine device upon enrollment and through 3 months after receiving the last dose of JSP191
Women not of childbearing potential must be post-menopausal (no menstrual period for a minimum of 12 months) or surgically sterilized and have a negative serum pregnancy test upon study entry
Male subjects must be surgically sterile or willing to use contraception upon enrollment and through 3 months after receiving the last dose of JSP191
Must be willing and able to provide informed consent
Exclusion Criteria:
Anemia secondary to iron deficiency, vitamin B12 deficiency, or folate deficiency
Prior allogeneic or autologous stem cell transplant
Known history of human immunodeficiency virus (HIV) (no laboratory testing is required), or active infection with hepatitis B or hepatitis C
Pregnant women or women who are nursing and do not wish to discontinue breastfeeding
Any other medical condition that, in the opinion of the Investigator, could pose a significant safety risk to the subject or jeopardize the integrity of the study
Subjects who, in the opinion of the Investigator, may not be able to comply with the requirements of the study
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Tampa Florida, 33612, United States
How clear is this clinincal trial information?